同仁堂集团立即开展零容忍品牌严管专项行动，已采取如下措施： 一、派专项工作组到四川，对涉事产品开展全面深入核查，坚决一查到底。 二、责令并监督涉事经销主体四川健康立即下架涉事产品，严格按照监管部门要求依法依规对消费者进行赔偿。 三、依法追究四川健康、哈博药业及相关电商平台的商标侵权等责任。对其违法使用"北京同仁堂"字样，误导消费者判断，损害消费者合 法权益的行为追究法律责任。四、对四川健康及其控股股东健康药业等单位在经营、管理、监督环节存在的问题开展问责，严肃追究相关 人员责任。 为进一步保护消费者权益，强化品牌保护责任，同仁堂集团同时开展以下工作： 北京同仁堂发布致歉声明称，针对近日有关"南极磷虾油"的舆论关注，集团对因此给消费者造成的权益损害，向广大消费者和社会各界致 以最诚恳的歉意。 来源：财联社 一、全面排查品牌使用中的违法违规行为，对集团各级企业的品牌使用情况进行拉网式核查。 二、全面开展品牌清理行动，坚决清理"擦边"使用"同仁堂"字号、商标使用不规范等行为，严格规范品牌管理体系。 三、全面规范电商平台授权店铺标识，严格使用"同仁堂"双龙图案商标，主动引导消费者准确识别正规购买渠道。 关注" 新华网 ...

12月20日，中国北京同仁堂（集团）有限责任公司发布声明，就此前"南极磷虾油造假风波"致歉，表示 将全面开展品牌清理行动，坚决清理"擦边"使用"同仁堂"字号、商标使用不规范等行为，严格规范品牌 管理体系。 声明全文如下—— 针对近日有关"南极磷虾油"的舆论关注，北京同仁堂集团高度重视、深感痛心，对因此给消费者造成的 权益损害，向广大消费者和社会各界致以最诚恳的歉意！同仁堂集团立即开展零容忍品牌严管专项行 动，已采取如下措施： 一、派专项工作组到四川，对涉事产品开展全面深入核查，坚决一查到底。 二、责令并监督涉事经销主体四川健康立即下架涉事产品，严格按照监管部门要求依法依规对消费者进 行赔偿。 一、全面排查品牌使用中的违法违规行为，对集团各级企业的品牌使用情况进行拉网式核查。 二、全面开展品牌清理行动，坚决清理"擦边"使用"同仁堂"字号、商标使用不规范等行为，严格规范品 牌管理体系。 三、全面规范电商平台授权店铺标识，严格使用"同仁堂"双龙图案商标，主动引导消费者准确识别正规 购买渠道。 "同仁堂"品牌创立356年来，始终离不开广大消费者的支持和厚爱。我们心怀感恩，诚恳接受社会各界 的监督与批评，愿意与大家一道 ...

Core Viewpoint - Tongrentang Group has issued an apology regarding the recent controversy over "Antarctic krill oil," acknowledging the damage caused to consumer rights and committing to a zero-tolerance approach towards brand management [1] Group 1: Company Response - Tongrentang Group has initiated a special action for strict brand management, deploying a task force to Sichuan for a comprehensive investigation of the involved products [1] - The company has ordered the immediate removal of the implicated products from the market and is ensuring compliance with regulatory requirements for consumer compensation [1] - Legal actions will be pursued against Sichuan Health, Habao Pharmaceutical, and related e-commerce platforms for trademark infringement and misleading consumers [1] Group 2: Product Investigation - The Shanghai Consumer Protection Committee conducted tests on 15 popular Antarctic krill oil products, revealing that the "Beijing Tongrentang 99% High Purity Antarctic Krill Oil" had a phospholipid content of 0, indicating potential fraud [3] - The implicated product was not directly produced by Beijing Tongrentang but was distributed by its subsidiary, Sichuan Health Pharmaceutical, with manufacturing outsourced to Habao Pharmaceutical [5] Group 3: Brand Management Issues - Habao Pharmaceutical admitted to not adding the claimed "Antarctic krill oil" during production, and the product packaging was created per the requirements of Sichuan Health Pharmaceutical [5] - The unauthorized use of the "Beijing Tongrentang" name on the product has led to legal proceedings initiated by the company against the involved parties [5] - There are concerns within the industry regarding Tongrentang's brand authorization management and quality control of its subsidiary products, which have contributed to a decline in consumer trust [6]

Core Viewpoint - Beijing Tongrentang Group expresses deep concern and regret over recent public attention regarding "Antarctic Krill Oil," and has initiated a series of measures to protect consumer rights and uphold brand integrity [1][2]. Group 1: Immediate Actions Taken - A special task force has been dispatched to Sichuan to conduct a thorough investigation of the involved products [1]. - The company has ordered the immediate removal of the implicated products from the market and will ensure compliance with regulatory requirements for consumer compensation [1]. - Legal actions will be pursued against Sichuan Health, Habao Pharmaceutical, and related e-commerce platforms for trademark infringement and misleading practices that harm consumer rights [1]. Group 2: Brand Protection Initiatives - A comprehensive review of brand usage violations across all levels of the group is being conducted to identify and rectify any illegal or non-compliant practices [2]. - A brand cleanup initiative is underway to eliminate improper use of the "Tongrentang" name and ensure strict adherence to brand management standards [2]. - The company is standardizing the branding of authorized e-commerce stores to ensure the correct use of the "Tongrentang" double-dragon logo, guiding consumers to recognize legitimate purchasing channels [2].

Core Viewpoint - The company is taking immediate and strict actions to protect its brand and consumer rights in response to allegations of false advertising related to a product marketed under its name. Group 1: Brand Protection Measures - The company has initiated a zero-tolerance brand management action, which includes legal accountability for trademark infringement against Sichuan Health, Habo Pharmaceutical, and related e-commerce platforms for misleading consumers [1] - A comprehensive investigation into brand usage violations across all subsidiaries is being conducted to ensure compliance with brand management standards [1] - The company is enforcing strict regulations on e-commerce platform store identifiers to ensure accurate representation of its brand and products [1] Group 2: Response to Allegations - Following allegations of false labeling of a product claiming to contain high levels of phospholipids, the company clarified that the involved entity, Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., is not a subsidiary of the company [4] - The company has dispatched a special task force to Sichuan to conduct a thorough investigation into the product in question and has mandated the immediate removal of the product from shelves [5] - The company emphasizes that it focuses on the production and sale of its own pharmaceutical products, with no outsourcing to third parties, ensuring the integrity of its offerings [9]

声明称，同仁堂已派专项工作组赴四川核查涉事产品，责令涉事经销主体下架产品并依法赔偿消费者， 同时依法追究四川健康、哈博药业及相关电商平台的商标侵权等责任。此外，为进一步保护消费者权 益，强化品牌保护责任，同仁堂集团还将开展品牌使用拉网式排查、清理"擦边"字号及不规范商标使用 行为，并规范电商平台授权店铺标识，引导消费者识别正规渠道。 北京商报讯（记者 王寅浩 宋雨盈）12月20日，北京同仁堂集团发布声明，就"南极磷虾油"事件引发的 消费者权益损害问题致歉，并宣布开展品牌严管专项行动。 ...

来源 | 北京同仁堂官微 中国北京同仁堂（集团）有限责任公司12月20日发布声明： 针对近日有关"南极磷虾油"的舆论关注，北京同仁堂集团高度重视、深感痛心，对因此给消费者造成的 权益损害，向广大消费者和社会各界致以最诚恳的歉意！同仁堂集团立即开展零容忍品牌严管专项行 动，已采取如下措施： 一、派专项工作组到四川，对涉事产品开展全面深入核查，坚决一查到底。 四、对四川健康及其控股股东健康药业等单位在经营、管理、监督环节存在的问题开展问责，严肃追究 相关人员责任。 为进一步保护消费者权益，强化品牌保护责任，同仁堂集团同时开展以下工作： 一、全面排查品牌使用中的违法违规行为，对集团各级企业的品牌使用情况进行拉网式核查。 二、全面开展品牌清理行动，坚决清理"擦边"使用"同仁堂"字号、商标使用不规范等行为，严格规范品 牌管理体系。 三、全面规范电商平台授权店铺标识，严格使用"同仁堂"双龙图案商标，主动引导消费者准确识别正规 购买渠道。 "同仁堂"品牌创立356年来，始终离不开广大消费者的支持和厚爱。我们心怀感恩，诚恳接受社会各界 的监督与批评，愿意与大家一道，共同守护好"同仁堂"金字招牌，以实际行动维护"同仁堂"的品牌 ...

Core Viewpoint - Beijing Tongrentang Group issued an apology regarding the Antarctic krill oil incident, emphasizing a zero-tolerance policy towards brand management and consumer protection [1][2]. Group 1: Company Actions - The company has initiated a special task force to conduct a thorough investigation of the involved products in Sichuan, ensuring a comprehensive inquiry [2]. - The company has ordered the immediate removal of the implicated products from the market and is supervising compliance with regulatory requirements for consumer compensation [2]. - Legal actions will be pursued against Sichuan Health, Habao Pharmaceutical, and related e-commerce platforms for trademark infringement and misleading consumers [2][3]. Group 2: Brand Protection Measures - The company is conducting a comprehensive review of brand usage to identify any illegal or non-compliant practices across its subsidiaries [2]. - A brand cleanup initiative is underway to eliminate improper use of the "Tongrentang" name and ensure strict adherence to brand management standards [2]. - The company is standardizing e-commerce platform store identifiers to ensure the correct use of the "Tongrentang" double-dragon logo, guiding consumers to recognize legitimate purchasing channels [3]. Group 3: Incident Background - A product labeled as "Beijing Tongrentang 99% High Purity Antarctic Krill Oil" was found to falsely claim high phospholipid content, with testing revealing a phospholipid content of 0% [3]. - The implicated product was produced by Anhui Habao Pharmaceutical Co., Ltd., and distributed by Sichuan Tongrentang Health Pharmaceutical Co., Ltd., which is a subsidiary of Beijing Tongrentang Group [3][7]. - The company clarified that Sichuan Tongrentang Health Pharmaceutical is not a direct subsidiary of Beijing Tongrentang but is under the control of its parent company [7].

四、对四川健康及其控股股东健康药业等单位在经营、管理、监督环节存在的问题开展问责，严肃追究 相关人员责任。 为进一步保护消费者权益，强化品牌保护责任，同仁堂集团同时开展以下工作： 一、全面排查品牌使用中的违法违规行为，对集团各级企业的品牌使用情况进行拉网式核查。 二、全面开展品牌清理行动，坚决清理"擦边"使用"同仁堂"字号、商标使用不规范等行为，严格规范品 牌管理体系。 12月20日，北京同仁堂集团发表声明： 针对近日有关"南极磷虾油"的舆论关注，北京同仁堂集团高度重视、深感痛心，对因此给消费者造成的 权益损害，向广大消费者和社会各界致以最诚恳的歉意！同仁堂集团立即开展零容忍品牌严管专项行 动，已采取如下措施： 一、派专项工作组到四川，对涉事产品开展全面深入核查，坚决一查到底。 二、责令并监督涉事经销主体四川健康立即下架涉事产品，严格按照监管部门要求依法依规对消费者进 行赔偿。 三、依法追究四川健康、哈博药业及相关电商平台的商标侵权等责任。对其违法使用"北京同仁堂"字 样，误导消费者判断，损害消费者合法权益的行为追究法律责任。 （文章来源：上海证券报） 三、全面规范电商平台授权店铺标识，严格使用"同仁堂"双龙 ...

Core Viewpoint - Beijing Tongrentang Group issued an apology regarding the Antarctic krill oil incident, emphasizing a zero-tolerance policy towards brand management and consumer protection [2][3]. Group 1: Actions Taken by the Company - A special task force has been dispatched to Sichuan to conduct a thorough investigation of the involved products [3]. - The company has ordered the immediate removal of the implicated products from the market and will ensure compensation to consumers as per regulatory requirements [4]. - Legal actions will be pursued against Sichuan Health, Habao Pharmaceutical, and related e-commerce platforms for trademark infringement and misleading consumers [4]. - Accountability measures will be implemented for Sichuan Health and its parent company regarding operational and management issues [4]. Group 2: Brand Protection Initiatives - A comprehensive review of brand usage violations across all subsidiaries will be conducted [5]. - A brand cleanup initiative will be launched to eliminate improper use of the "Tongrentang" name and ensure compliance with brand management standards [6]. - E-commerce platform stores will be required to strictly use the "Tongrentang" double-dragon logo to help consumers identify legitimate purchasing channels [7]. Group 3: Incident Background - A product labeled as "Beijing Tongrentang 99% High Purity Antarctic Krill Oil" was found to falsely claim high phospholipid content, with actual testing revealing a phospholipid content of 0% [7]. - The implicated product was produced by Anhui Habao Pharmaceutical and distributed by Sichuan Tongrentang Health, which is not a direct subsidiary of Beijing Tongrentang [7][10]. - The company clarified that it focuses on the production and sale of traditional Chinese medicine, with over 400 product specifications, and does not outsource production to third parties [10].